Summary & Overview
Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview
DRG 825 includes admissions for lymphoma and non-acute leukemia with other procedures when no Complication or Comorbidity or Major Complication or Comorbidity is present; it addresses cases with operative intervention but lower documented clinical severity. This grouping matters for inpatient reimbursement because it assigns the Centers for Medicare & Medicaid Services payment relative to expected resource use for these moderate-severity surgical admissions.
DRG 825 Overview
DRG 825 covers inpatient admissions for patients with lymphoma and non-acute leukemia who undergo other procedures without a Complication or Comorbidity or Major Complication or Comorbidity. This category groups cases where the principal diagnosis is a lymphoid malignancy and a secondary operative procedure is performed that does not meet higher-severity grouping criteria. It matters for Centers for Medicare & Medicaid Services payment because it defines a specific payment weight reflecting average resource use for these less complex procedural admissions. Accurate coding of diagnoses and procedures determines inclusion in this Diagnosis-Related Group and affects Medicare inpatient reimbursement.
Clinical Trials
- Trials evaluating peri-procedural optimization and complication reduction for patients with lymphoma or chronic (non-acute) leukemia undergoing other invasive procedures (such as biopsy, central line placement, or minor surgical interventions). These studies enroll inpatients with active lymphoma or indolent/non-acute leukemia who require procedural interventions to characterize bleeding, infection, and wound-healing risks, and test standardized preoperative assessment and prophylaxis protocols. Results are highly relevant to providers for reducing procedure-related morbidity and to payers because lower complication rates can shorten length of stay and reduce downstream costs.
- Comparative effectiveness studies of chemoimmunotherapy sequencing or supportive-care bundles in the non-acute leukemia/lymphoma inpatient population receiving non-definitive procedures. These trials compare timing and sequencing of systemic therapy relative to procedures (for example deferring versus initiating certain systemic agents around invasive procedures) and assess short-term outcomes such as transfusion needs, febrile neutropenia, and inpatient resource utilization. Findings inform clinicians about balancing disease control with procedural safety and help payers evaluate which care pathways yield better value by reducing readmissions and intensive-support use.
- Post-discharge outcomes and care coordination studies focused on transitions from inpatient stays where other procedures were performed to outpatient oncology management. These observational or pragmatic interventional studies follow patients with lymphoma or chronic leukemia after discharge to measure adherence to follow-up, delays in planned therapy, rates of readmission for infection or complication, and patient-reported functional recovery. This research addresses gaps in continuity of care that affect clinical outcomes and is pertinent to payers and health systems aiming to improve readmission rates, optimize post-acute resource allocation, and align reimbursement with quality transitions.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.